Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 73.3% in May

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totaling 12,126 shares, a growth of 73.3% from the April 30th total of 6,999 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 23,966 shares, the days-to-cover ratio is presently 0.5 days.

Bolt Biotherapeutics Price Performance

Shares of BOLT traded down $0.20 during trading hours on Tuesday, hitting $5.11. 12,661 shares of the stock were exchanged, compared to its average volume of 26,139. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The stock’s 50-day moving average price is $4.75 and its two-hundred day moving average price is $5.09. The company has a market cap of $9.81 million, a price-to-earnings ratio of -0.31 and a beta of 1.12. Bolt Biotherapeutics has a 12-month low of $3.91 and a 12-month high of $7.35.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. Research analysts expect that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

Several large investors have recently added to or reduced their stakes in BOLT. Squarepoint Ops LLC grew its holdings in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares in the last quarter. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics in the 3rd quarter valued at $85,000. Susquehanna International Group LLP purchased a new stake in Bolt Biotherapeutics in the 3rd quarter valued at $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Bolt Biotherapeutics in the 4th quarter valued at $112,000. Finally, T3 Companies LLC purchased a new stake in Bolt Biotherapeutics in the 4th quarter valued at $208,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on BOLT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on Bolt Biotherapeutics in a research report on Thursday. They set a “buy” rating and a $22.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $34.67.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.